combigan 2 mg/ml + 5 mg/ml ögondroppar, lösning
orifarm ab - brimonidintartrat; timololmaleat - Ögondroppar, lösning - 2 mg/ml + 5 mg/ml - timololmaleat 6,8 mg aktiv substans; brimonidintartrat 2 mg aktiv substans; bensalkoniumklorid hjälpämne
methotrexate paranova 100 mg/ml koncentrat till infusionsvätska, lösning
paranova läkemedel ab - metotrexat - koncentrat till infusionsvätska, lösning - 100 mg/ml - metotrexat 100 mg aktiv substans
roctavian
biomarin international limited - valoctocogene roxaparvovec - hemostatika - treatment of severe haemophilia a (congenital factor viii deficiency) in adult patients without a history of factor viii inhibitors and without detectable antibodies to adeno-associated virus serotype 5 (aav5).
rhesonativ 750 ie/ml injektionsvätska, lösning
octapharma ab - anti-d immunglobulin, humant - injektionsvätska, lösning - 750 ie/ml - anti-d immunglobulin, humant 750 ie aktiv substans
nevirapine mylan 400 mg depottablett
mylan ab - nevirapin (vattenfritt) - depottablett - 400 mg - laktosmonohydrat hjälpämne; nevirapin (vattenfritt) 400 mg aktiv substans
nevirapine teva b.v. 400 mg depottablett
teva b.v. - nevirapin (vattenfritt) - depottablett - 400 mg - nevirapin (vattenfritt) 400 mg aktiv substans
upstaza
ptc therapeutics international limited - eladocagene exuparvovec - aminosyrametabolism, infödda fel - enzymes, other alimentary tract and metabolism products - upstaza is indicated for the treatment of patients aged 18 months and older with a clinical, molecular, and genetically confirmed diagnosis of aromatic l amino acid decarboxylase (aadc) deficiency with a severe phenotype (see section 5.
comirnaty
biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vacciner - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. användning av detta vaccin bör ske i enlighet med officiella rekommendationer.
covid-19 vaccine (inactivated, adjuvanted) valneva
valneva austria gmbh - covid-19 vaccine (inactivated, adjuvanted, adsorbed) - covid-19 virus infection - vacciner - covid-19 vaccine (inactivated, adjuvanted) valneva is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 to 50 years of age. the use of this vaccine should be in accordance with official recommendations.
nevirapine medical valley 400 mg depottablett
medical valley invest ab - nevirapin (vattenfritt) - depottablett - 400 mg - nevirapin (vattenfritt) 400 mg aktiv substans; laktosmonohydrat hjälpämne